Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common antibiotic could shield hearts after attack

NCT ID NCT03508232

Disease control Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a short course of doxycycline, a common antibiotic, can prevent heart damage after a heart attack. 174 adults who had a severe heart attack received either doxycycline or a placebo twice daily for one week. Researchers then used MRI scans to check heart structure three months later, hoping to see less scarring and better heart function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Doxycycline
What this could lead to
If it works, this could point toward a simple, short-term treatment to protect the heart after a heart attack and reduce the risk of future heart failure.
What could go wrong
This is a small pilot study, so results may not be conclusive. Doxycycline is not yet proven for this use, and the benefit may be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

174 people

The number who actually took part.

Started

Jan 2020

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18+ year old 2. Diagnosis of acute ST-elevation myocardial infarction (STEMI) 3. Primary STEMI 4. Symptom onset of less than 12 hours 5. Admitted to the Royal Alexandra Hospital in Edmonton, Alberta Exclusion Criteria: 1. Low risk inferior STEMI (total ST elevation plus depression \<4mm) 2. Cardiogenic shock 3. Use of thrombolytics 4. Prior history of myocardial infarction or heart failure 5. Known hypersensitivity to tetracyclines 6. Any concurrent medical condition expected to reduce life expectancy to \<1 year 7. Symptom onset to treatment (loading dose) time longer than 24 hours 8. Poor renal function (eGFR\<30 mL/min/1.73m2) or other contraindications to MRI (claustrophobia, pregnancy, PPM/ICD, sub-arachnoid clips, retained ocular foreign body)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure ST-segment elevation myocardial infarction

Contacts and locations

Locations

  • Royal Alexandra Hospital

    Edmonton, Alberta, T5H 3V9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.